

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Weshington, D.C. 20231 www.uspto.gov

FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
MARC ALIZON	3495.0010-24	4214	
FINNEGAN, HENDERSON, FARABOW, GARRETT &		EXAMINER	
DUNNER LLP 1300 I STREET, NW			
			WASHINGTON, DC 20005
	1637	26	
	DATE MAILED: 05/22/2002	20	
	MARC ALIZON	MARC ALIZON 3495.0010-24 RABOW, GARRETT & EXAMI FREDMAN, JEFF ART UNIT 1637	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
		08/475,822	ALIZON ET AL.		
	Office Action Summary	Examiner	Art Unit		
		Jeffrey Fredman	1637		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1)🖂	Responsive to communication(s) filed on <u>24 December 1996</u> .				
2a) <u></u> □	This action is FINAL . 2b)⊠ Thi	s action is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
•	ion of Claims				
4)⊠ Claim(s) <u>11-18</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>11-18</u> is/are rejected.					
<u> </u>	7) Claim(s) is/are objected to.				
8) Claim(s) are subject to restriction and/or election requirement. Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
	1. Certified copies of the priority documents have been received.				
	2. Certified copies of the priority documents have been received in Application No				
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 					
Attachment(s)					
2) Notic	e of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)		

Art Unit: 1637

DETAILED ACTION

Status

- 1. This rejection is non-final. It is noted that this application was suspended pending the result of Interference 102,822, which interference was resolved in favor of the other party. Therefore, the Chang et al patent, cited below in the 102 rejections, is properly 102(e) art which cannot be rebutted due to res judicata.
- 2. Separately, Applicant is requested, in any response to this office action, to submit a copy of the original claims which were submitted for interference, in order to determine which claims, if any, should be cancelled under 37 CFR 1.663.

Double Patenting

3. Claims 17 and 18 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 13 of copending Application No. 08/308,218 in view of White et al (U.S. Patent 4,677,054).

Although the conflicting claims are not identical, they are not patentably distinct from each other because both claims are drawn to the identical products, the HIV ORF R, with the current claim 17 simply including reagents for the hybridization reaction including controls and claim 18 further teaching the use of labels.

Claim 13 of copending application No. 08/308,218 teaches the HIV ORF-R sequence. The claim does not teach hybridization reagents or labels.

White teaches labeling probes and hybridization reagents using radioactive labels for detection of nucleic acids including RNA from animal tissue by hybridization (column 2, lines 6-34).

Art Unit: 1637

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to combine the method of White with the method of Claim 13 of copending application No. 08/308,218 because White states that the method is widely applicable, stating "It will be obvious to those skilled in the art that the method of the present invention is general in scope and can be used for DNA and mRNA-like analysis of all sorts of biological specimens (column 2, lines 40-44)." Further motivation to detect using these methods is provided by White, who notes "Very small amounts of sample can be tested. Furthermore, the samples can be hybridized with multiple probes used in sequence (column 3, lines 2-4)". An ordinary practitioner would have been motivated to use the labels of White since White says that the method is broadly applicable, permits the use of small sample amounts and permits detection using multiple different probes to enhance specificity.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

4. Claims 15 and 16 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 11-22 of copending Application No. 08/202,239 in view of White et al (U.S. Patent 4,677,054).

Although the conflicting claims are not identical, they are not patentably distinct from each other because both claims are drawn to the identical products, the HIV ORF R, with the current claim 17 simply including reagents for the hybridization reaction including controls and claim 18 further teaching the use of labels.

Art Unit: 1637

Claims 11-22 of copending Application No. 08/202,239 teaches the HIV ORF-Q, ORF-1, ORF-2, ORF-3, ORF-4 and ORF-5 sequence. The claims also teach the use of labels. The claim does not teach hybridization reagents.

White teaches labeling probes and hybridization reagents using radioactive labels for detection of nucleic acids including RNA from animal tissue by hybridization (column 2, lines 6-34).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to combine the method of White with the method of claims 11-22 of copending Application No. 08/202,239 because White states that the method is widely applicable, stating "It will be obvious to those skilled in the art that the method of the present invention is general in scope and can be used for DNA and mRNA-like analysis of all sorts of biological specimens (column 2, lines 40-44)." Further motivation to detect using these methods is provided by White, who notes "Very small amounts of sample can be tested. Furthermore, the samples can be hybridized with multiple probes used in sequence (column 3, lines 2-4)". An ordinary practitioner would have been motivated to use the labels of White since White says that the method is broadly applicable, permits the use of small sample amounts and permits detection using multiple different probes to enhance specificity.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11

Art Unit: 1637

F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

7. Claims 11, 13, 15 and 17 are rejected under 35 U.S.C. 102(e) as being anticipated by Chang et al (U.S. Patent 6,001,977).

The claims utilize the open "having" language which permits the inclusion of additional elements. "Having" is interpreted as being of identical scope to "comprising".

Art Unit: 1637

Chang teaches in vitro diagnostic methods for detecting the presence or absence of HIV-1 virus in a biological sample (column 9, lines 25-62) comprising:

contacting said biological sample with a nucleic acid probe of HIV-1 selected from the HIV sequence (column 9, lines 25-62 and column 10, line 65 to column 11, line 32),

where the specific sequence is disclosed as SEQ ID NO: 4, for example (columns 19-28).

And detecting the formation of hybrids in the biological sample (column 9, lines 25-62).

Chang further teaches the compositions of these nucleic acids (column 9, lines 25-62) as well as HTLV-I and II negative control sequences (column 9, lines 25-62).

The alignment of the Query HIV sequences of Chang and the subject sequences of the present application in the region between nucleotides 4000 and 9000 are presented below.

Query: 4010 ttccctacaatccccaaagtcaaggagtagtagaatctatgaataaagaattaaagaaaa 4069

Query: 4190 tagacataatagcaacagacatacaaactaaagaattacaaaacaaattacaaaaattc 4249

Application/Control Number: 08/475,822

Art Unit: 1637

Sbjct: 4377 tagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattc 4436 916 V D I I A T D I Q T K E L Q K Q I T K I Query: 4250 aaaattttcgggtttattacagggacagcagaaatccactttggaaaggaccagcaaagc 4309 Sbjct: 4437 aaaattttcgggtttattacagggacagcagagatccactttggaaaggaccagcaaagc 4496 936 Q N F R V Y Y R D S R D P L W K G P A K Query: 4310 tcctctggaaaggtgaaggggcagtagtaatacaagataatagtgacataaaagtagtgc 4369 Sbjct: 4497 tcctctggaaaggtgaaggggcagtagtaatacaagataatagtgacataaaagtagtgc 4556 956 L L W K G E G A V V I Q D N S D I K V V pol Query: 4370 caagaagaaaagcaaagatcattagggattatggaaaacagatggcaggtgatgattgtg 4429 Sbjct: 4557 caagaagaaaagcaaagatcattagggattatggaaaacagatggcaggtgattgtg 4616 976 P R R K A K I I R D Y G K Q M A G D D C pol Query: 4430 tggcaagtagacaggattaggattagaacatggaaaagtttagtaaaacaccatatgtat 4489 Sbjct: 4617 tggcaagtagacaggatgaggattagaacatggaaaagtttagtaaaacaccatatgtat 4676 996 V A S R O D E D ^^^ pol Query: 4490 gtttcagggaaagctaggggatggttttatagacatcactatgaaagccctcatccaaga 4549 Sbjct: 4677 gtttcagggaaagctaggggatggttttatagacatcactatgaaagccctcatccaaga 4736 Query: 4550 ataagttcagaagtacacatcccactaggggatgctagattggtaataacaacatattgg 4609 Sbjct: 4737 ataagttcagaagtacacatcccactaggggatgctagattggtaataacaacatattgg 4796 Query: 4610 ggtctgcatacaggagaaagagactggcatttgggtcagggagtctccatagaatggagg 4669 Sbjct: 4797 ggtctgcatacaggagaaagagactggcatctgggtcagggagtctccatagaatggagg 4856 Query: 4670 aaaaagagatatagcacacaagtagaccctgaactagcagaccaactaattcatctgtat 4729 Sbjct: 4857 aaaaagagatatagcacacaagtagaccctgaactagcagaccaactaattcatctgtat 4916 Query: 4730 tactttgactgtttttcagactctgctataagaaaggccttattaggacacatagttagc 4789 Sbjct: 4917 tactttgactgtttttcagactctgctataagaaaggccttattaggacatatagttagc 4976

Application/Control Number: 08/475,822

Art Unit: 1637

Query: 4790 cctaggtgtgaatatcaagcaggacataacaaggtaggatctctacaatacttggcacta 4849 Sbjct: 4977 cctaggtgtgaatatcaagcaggacataacaaggtaggatctctacaatacttggcacta 5036 Query: 4850 gcagcattaataacaccaaaaaagataaagccacctttgcctagtgttacgaaactgaca 4909 Sbjct: 5037 gcagcattaataacaccaaaaaagataaagccacctttgcctagtgttacgaaactgaca 5096 Query: 4910 gaggatagatggaacaagccccagaagaccaagggccacagagggagccacacaatgaat 4969 Sbjct: 5097 gaggatagatggaacaagccccagaagaccaagggccacagagggagccacacaatgaat 5156 Query: 4970 ggacactagagcttttagaggagcttaagaatgaagctgttagacattttcctaggattt 5029 Sbjct: 5157 ggacactagagcttttagaggagcttaagaatgaanctgttagacattttcctaggattt 5216 Query: 5030 ggctccatggcttagggcaacatatctatgaaacttatggggatacttgggcaggagtgg 5089 Sbjct: 5217 ggctccatggcttagggcaacatatctatgaaacttatggggatacttgggcaggagtgg 5276 Query: 5090 aagccataataagaattctgcaacaactgctgtttatccattttcagaattgggtgtcga 5149 Sbjct: 5277 aagccataataagaattetgcaacaactgntgtttatcca-tttcagaattgggtgtcga 5335 Query: 5150 catagcagaataggcgttactcgacagaggagagcaagaaatggagccagtagatcctag 5209 Sbjct: 5336 catagcagaataggcgttactcaacagaggagagcaagaaatggagccagtagatcctag 5395 Query: 5210 actagagccctggaagcatccaggaagtcagcctaaaactgcttgtaccaattgctattg 5269 Sbjct: 5396 actaganccctggaagcatccaggaagtcagcctaaaactgcttgtaccacttnntattg 5455 Query: 5270 taaaaagtgttgctttcattgccaagtttgtttcataacaaaagccttaggcatctccta 5329 Sbjct: 5456 taaaaagtgttgctttcattgccaagtttgtttcacaacaaaagccttaggcatctccta 5515 orfQ CQVCFTTKALGISY Query: 5330 tggcaggaagaagcggagacagcgaagacctcctcaaggcagtcagactcatcaagt 5389 Sbjct: 5516 tggcannaagaagcggagacagcgacgaagacctcctcaaggcagtcagactcatcaagt 5575 G X K K R R Q R R R P P Q G S Q T H Q V orfQ Query: 5390 ttctctatcaaagcagtaagtagtacatgtaatgcaacctatacaaatagcaatagtagc 5449

Application/Control Number: 08/475,822

Art Unit: 1637

Sbjct: 5576 ttctctatcaaagcagtaagtagtacatgtaatgcaacctatacaaatagcaatagcagc 5635

orfQ 35 S L S K Q ^^^

Query: 5450 attagtagtagcaataataatagcaatagttgtgtgtgtccatagtaatcatagaatatag 5509

Sbjct: 5636 attagtagtagcaataataatagcaatagttgtgtgtgtccatagtaatcatagaatatag 5695

Query: 5510 gaaaatattaagacaaagaaaatagacaggttaattgatagactaatagaaagagcaga 5569

Sbjct: 5696 gaaaatattaagacaagaaaaatagacaggttaattgatagactaatagaaagagcaga 5755

env 1 K E Q

Query: 5570 agacagtggcaatgagagtgaaggagaaatatcagcacttgtggagatgggggtggagat 5629

env 4 K T V A M R V K E K Y O H L W R W G W K

Query: 5630 ggggcaccatgctccttgggatgttgatgatctgtagtgctacagaaaaattgtgggtca 5689

Sbjct: 5816 ggggcaccatgctccttgggatattgatgatctgtagtgctacagaaaaattgtgggtca 5875 env 24 W G T M L L G I L M I C S A T E K L W V

Query: 5690 cagtctattatggggtacctgtgtggaaggaagcaaccaccactctattttgtgcatcag 5749

Sbjct: 5876 cagtctattatggggtacctgtgtggaaggaagcaaccaccactctattttgtgcatcag 5935

env 44 TVYYGVPVWKEATTTLFCAS

Query: 5750 atgctaaagcatatgatacagaggtacataatgtttgggccacacatgcctgtgtaccca 5809

Sbjct: 5936 atgctaaagcatatgatacagaggtacataatgtttgggccacacatgcctgtgtaccca 5995

env 64 D A K A Y D T E V H N V W A T H A C V P

Query: 5810 cagaccccaacccacaagaagtagtattggtaaatgtgacagaaaattttaacatgtgga 5869

Sbjct: 5996 cagaccccaacccacagaagtagtattggtaaatgtgacagaaaattttaacatgtgga 6055

env 84 T D P N P Q E V V L V N V T E N F N M W

Query: 5870 aaaatgacatggtagaacagatgcatgaggatataatcagtttatgggatcaaagcctaa 5929

Sbjct: 6056 aaaatgacatggtagaacagatgcatgaggatataatcagtttatgggatcaaagcctaa 6115

env 104 K N D M V E Q M H E D I I S L W D Q S L

Query: 5930 agccatgtgtaaaattaaccccactctgtgttagtttaatttaaagtgcactgatttgaagaatg 5989

Sbjct: 6116 agccatgtgtaaaattaaccccactctgtgttagtttaaagtgcactgatttggggaatg 6175

Art Unit: 1637

124 K P C V K L T P L C V S L K C T D L G N env

Query: 5994 taataccaatagtagtagcgggagaatgataatggagaaaggagagataaaaaactgctc 6053

N T N S S S G E M M M E K G E I K N C S env

F N I S T S I R G K V Q K E Y A F F Y K env

Query: 6114 acttgatataataccaatagataatgatactaccagctatacgttgacaagttgtaacac 6173

Sbjct: 6315 acttgatataataccaatagataatgatactaccagctatacgttgacaagttgtaacac 6374

LDIIPIDNDTTSYTLTSCNT

Query: 6174 ctcaqtcattacacaqqcctqtccaaaqqtatcctttqaqccaattcccatacattattq 6233

Sbjct: 6375 ctcagtcattacacaggcctgtccaaaggtatcctttgagccaattcccatacattattg 6434 211 S V I T Q A C P K V S F E P I P I H Y C

Query: 6234 tgccccggctggtttttgcgattctaaaatgtaataataagacgttcaatggaacaggacc 6293

Sbjct: 6435 tgccccggctggttttgcgattctaaaatgtaataataagacgttcaatggaacaggacc 6494 A P A G F A I L K C N N K T F N G T G P env

Query: 6294 atgtacaaatgtcagcacagtacaatgtacacatggaattaggccagtagtatcaactca 6353

Sbjct: 6495 atgtacaaatgtcagcacagtacaatgtacacatggaattaggccagtagtatcaactca 6554

C T N V S T V Q C T H G I R P V V S T Q env

Query: 6354 actgctgttaaatggcagtctggcagaagaagaggtagtaattagatctgccaatttcac 6413

Sbjct: 6555 actgctgttgaatggcagtctagcagaagaagaggtagtaattagatctgccaatttcac 6614

LLLNGSLAEEEVVIRSANFT env

D N A K T I I V Q L N Q S V E I N C T R env

Query: 6474 acccaacaacaatacaagaaaaagtatccgtatccagagaggaccagggagagcatttgt 6533

Art Unit: 1637

Sbjct: 6675 acccaacaacaatacaagaaaaagtatccgtatccagaggggaccaggggagcatttgt 6734 311 PNNNTRKSIRIQRGPGRAFV Query: 6534 tacaataggaaaaataggaaatatgagacaaqcacattgtaacattagtagagcaaaatg 6593 Sbjct: 6735 tacaataggaaaataggaaatatgagacaagcacattgtaacattagtagagcaaaatg 6794 331 TIGKIGNMROAHCNISRAKW env Query: 6594 gaataacactttaaaacagatagatagcaaattaagagaacaatttggaaataataaaac 6653 Sbjct: 6795 gaatgccactttaaaacagatagctagcaaattaagagaacaatttggaaataataaaac 6854 NATLKQIASKLREQFGNNKT env Query: 6654 aataatctttaagcagtcctcaggaggggacccagaaattgtaacgcacagttttaattg 6713 Sbjct: 6855 aataatctttaagcaatcctcaggaggggacccagaaattgtaacgcacagttttaattg 6914 I I F K Q S S G G D P E I V T H S F N C env Query: 6714 tggaggggaatttttctactgtaattcaacacaactgtttaatagtacttggtttaatag 6773 Sbjct: 6915 tggaggggaatttttctactgtaattcaacacaactgtttaatagtacttggtttaatag 6974 G G E F F Y C N S T Q L F N S T W F N S Query: 6774 tacttggagtactaaagggtcaaataacactgaaggaagtgacacaatcaccctcccatg 6833 Sbjct: 6975 tacttggagtactgaagggtcaaataacactgaaggaagtgacacaatcacactcccatg 7034 TWSTEGSNNTEGSDTITLPC Query: 6834 cagaataaaacaaattataaacatgtggcaggaagtaggaaaagcaatgtatgcccctcc 6893 Sbjct: 7035 cagaataaaacaatttataaacatgtggcaggaagtaggaaaagcaatgtatgccctcc 7094 431 RIKOFINMWQEVGKAMYAPP env Query: 6894 catcagtggacaaattagatgttcatcaaatattacagggctgctattaacaagagatgg 6953 Sbjct: 7095 catcagcggacaaattagatgttcatcaaaatattacagggctgctattaacaagagatgg 7154 env I S G Q I R C S S N I T G L L T R D G Query: 6954 tggtaatagcaacaatgagtccgagatcttcagacctggaggaggagatatgagggacaa 7013 Sbjct: 7155 tqqtaataacaacaatqqqtccqaqatcttcagacctqqaqqqqatatqaqqqacaa 7214 471 G N N N N G S E I F R P G G G D M R D N Query: 7014 ttggagaagtgaattatataaaatataaagtagtaaaaattgaaccattaggagtagcacc 7073

Art Unit: 1637

env

Sbjct: 7215 ttqqaqaaqtqaattatataaaatataaaqtaqtaaaaattqaaccattaqqaqtaqcacc 7274 W R S E L Y K Y K V V K I E P L G V A P Query: 7074 caccaaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaataggagcttt 7133 Sbjct: 7275 caccaaggcaaagagaagagtggtgcagagagaaaaaaagagcagtgggaataggagcttt 7334 T K A K R R V V Q R E K R A V G I G A L Query: 7134 gttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacgctgac 7193 Sbjct: 7335 gttccttgggttcttgggagcagcaggaagcactatgggcgcacggtcaatgacgctgac 7394 F L G F L G A A G S T M G A R S M T L T env Query: 7194 ggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggc 7253 Sbjct: 7395 gqtacaggccagacaattattqtctqqtatagtqcagcagcagaacaatttqctqaqqqc 7454 551 V Q A R Q L L S G I V Q Q Q N N L L R A env Query: 7254 tattgaggcgcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggc 7313 Sbjct: 7455 tattgaggcqcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggc 7514 I E A O O H L L Q L T V W G I K Q L O A env Query: 7314 aagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggattttggggttg 7373 Sbjct: 7515 aagaatcctggctgtggaaagatacctaaaggatcaacagctcctgggnatttggggttg 7574 RILAVERYLKDQQLLGIWGC Query: 7374 ctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatc 7433 Sbjct: 7575 ctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatc 7634 S G K L I C T T A V P W N A S W S N K S env 611 Query: 7434 tctqqaacaqatttqqaataacatqacctqqatqqqqqtqqqacaqaqaattaacaatta 7493 Sbjct: 7635 tctggaacagatttggaataacatgacctggatggagtggacagagaaattaacaatta 7694 L E Q I W N N M T W M E W D R E I N N Y env Sbjct: 7695 cacaagcttaatacattccttaattgaagaatcgcaaaaccagcaagaaaagaatgaaca 7754

T S L I H S L I E E S Q N Q Q E K N E Q

Query: 7554 agaattattggaattagataaatgggcaagtttgtgggaattggtttaacataacaaattg 7613

Art Unit: 1637

Sbjct: 7755 agaattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattg 7814 env 671 E L L E L D K W A S L W N W F N I T N W

Query: 7614 gctgtggtatataaaattattcataatgatagtaggaggcttggtaggtttaagaatagt 7673

Sbjct: 7815 gctgtggtatataaaaatattcataatgataggaggcttggtaggtttaagaatagt 7874 env 691 L W Y I K I F I M I V G G L V G L R I V

Query: 7674 ttttgctgtactttctgtagtgaatagagttaggcagggatattcaccattatcgtttca 7733

Sbjct: 7875 ttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttca 7934 env 711 F A V L S I V N R V R O G Y S P L S F O

Query: 7734 gacccacctcccaatcccgaggggacccgacaggcccgaaggaatagaagaagatgg 7793

Sbjct: 7935 gacccacctcccaaccccgaggggacccgacaggcccgaaggaatagaagaagaaggtgg 7994 env 731 T H L P T P R G P D R P E G I E E E G G

Query: 7794 agagagagacagatccattcgattagtgaacggatccttagcacttatctggga 7853

Sbjct: 7995 agagagagacagagacagatccattcgattagtgaacggatccttagcacttatctggga 8054 env 751 E R D R D R S I R L V N G S L A L I W D

Query: 7854 cgatctgcggagcctgtgcctcttcagctaccaccgcttgagagacttactcttgattgt 7913

Sbjct: 8055 cgatctgcggagcctgtgcctcttcagctaccaccgcttgagagacttactcttgattgt 8114 env $\,$ 771 $\,$ D $\,$ L $\,$ R $\,$ S $\,$ L C $\,$ L $\,$ F $\,$ S $\,$ Y $\,$ H $\,$ R $\,$ L $\,$ R $\,$ D $\,$ L $\,$ L $\,$ I $\,$ V

Query: 7914 aacgaggattgtggaacttctgggacgcagggggtgggaagccctcaaatattggtggaa 7973

Query: 7974 tctcctacagtattggagtcaggagctaaagaatagtgctgttagcttgctcaatgccac 8033

env 811 L L Q Y W S Q E L K N S A V S L L N A T

Query: 8034 agctatagcagtagctgaggggacagatagggttatagaagtagtacaaggagcttatag 8093

Sbjct: 8235 agccatagcagtagctgagggnacagatagggttatagaagtagtacaaggagcttgtag 8294 env 831 A I A V A E G T D R V I E V V Q G A C R

Query: 8094 agctattcgccacatacctagaagaataagacagggcttggaaaggattttgctataaga 8153

Art Unit: 1637

Sbjct: 8295 agctattcgccacatacctagaagaataagacagggcttggaaaggattttgctataaga 8354

D R A W K G F C Y K AIRHIPRRIRQGLERILL^^^

env

Query: 8154 tgqqtqqcaaqtqqtcaaaaqtaqtqtqtqqttqqatqqcctqctqtaaqqqaaaqaatqa 8213

Sbjct: 8355 tqqqtqqcaaqtqqtcaaaaaqtaqtqtqtqttqqatqqcctactqtaaqqqaaaqaatqa 8414

11 MGGKWSKSSVVGWPTVRERM

Query: 8214 gacgagctgagccagcagcagatggggtgggagcagcatctcgagacctagaaaaacatg 8273

Sbjct: 8415 gacgagctgagccagcagcagatggggtgggagcatctcgagacctggaaaaacatg 8474 31 RRAEPAADGVGAASRDLEKH orfF

Query: 8274 gagcaatcacaagtagcaacacagcagctaacaatgctgattgtgcctggctagaagcac 8333

Sbjct: 8475 gagcaatcacaagtagcaatacagcagctaccaatgctgcttgtgcctggctagaagcac 8534

51 GAITSSNTAATNAACAWLEA orfF

Query: 8334 aaqaqqaqqaqqqtqqqttttccaqtcacacctcaqgtacctttaaqaccaatgactt 8393

Sbjct: 8535 aagaggaggaggaggtgggttttccactcacacctcaggtacctttaagaccaatgactt 8594

71 OEEEEVGFPLTPOVPLRPMT orfF

Query: 8394 acaaggcagctgtagatcttagccactttttaaaaagaaaaggggggactggaagggctaa 8453

Sbjct: 8595 acaaggcagctgtagatcttagccactttttaaaaggaaaaggggggactggaagggctaa 8654

91 Y K A A V D L S H F L K E K G G L E G L

111 I H S Q R R Q D I L D L W I Y H T Q G Y orfF

Query: 8514 tccctgattagcagaactacacaccagggccagggatcagatatccactgacctttggat 8573

Sbjct: 8715 tccctgattggcagaactacaccagggccaggggtcagatatccactgacctttggat 8774

131 F P D W Q N Y T P G P G V R Y P L T F G orfF

Query: 8574 ggtgctacaagctagtaccagttgagccagagaagttagaagaagccaacaaaggagaga 8633

Sbjct: 8775 gqtqctacaaqctagtaccagttqaqccagataaqqtaqaaqaqqccaataaaqqaqaqa 8834

151 W C Y K L V P V E P D K V E E A N K G E orfF

Query: 8634 acaccagcttqttacaccctqtqaqcctqcatqqaatgqatqacccqqaqaqaqaqtqt 8693

Art Unit: 1637

```
171 N T S L L H P V S L H G M D D P E R E V
orfF
Query: 8694 tagagtggaggtttgacagccgcctagcatttcatcacatggcccgagagctgcatccgg 8753
       Sbjct: 8895 tagagtggaggtttgacagccqcctagcatttcatcacgtggcccgagagctgcatccgg 8954
    191 LEWRFDSRLAFHHVARELHP
orfF
Query: 8754 agtacttcaagaactgctgacatcgagcttgctacaagggactttccgctggggactttc 8813
       Sbjct: 8955 agtacttcaagaactgctgacatcgagcttgctacaagggactttccgctggggactttc 9014
orfF
    211 E Y F K N C ^^^
Query: 8814 cagggaggcgtggcctgggcgggactggggagtggcgagccctcagatcctgcatataag 8873
        Sbjct: 9015 cagggaggcgtggcctggccgggactggggggtggcgagccctcagatgctgcatataan 9074
Query: 8874 caqctqctttttqcctqtactqqqtctctctqqttaqaccaqatctqaqcctqqqaqctc 8933
        Sbjct: 9075 cagctgctttttgcctgtactgggtctctctctggttagaccagattttgagcctgggagctc 9134
Score = 2796 bits (1454), Expect = 0.0
Identities = 1477/1489 (99%)
Strand = Plus / Plus
```

It is noted that with regard to, for example, the sequence region between nucleotides 4487 and 5086 claimed in claim 11, there are two nucleotide differences between the sequences. It is noted that the art recognizes that sequencing errors occur in a range between 0.3 % and 2.5%, as evidenced by Richterich (Genome Research (1998) 8:251-259). However, these error rates are determined using technology that was significantly more advanced than that in 1984, when sequencing error rates were likely significantly higher. In the 599 nucleotide sequence which is the first sequence of claim 1, two errors would represent approximately a 0.3% error rate. Thus, these sequences are identical within the error range available and the anticipation rejection is proper.

Application/Control Number: 08/475,822

Art Unit: 1637

With regard to the kit claims, it is noted that the preamble phrase "a kit" imposes no structural requirements upon the product claims.

Claim Rejections - 35 USC § 103

- 8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 9. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 10. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1637

11. Claims 11-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chang et al (U.S. Patent 6,001,977) as applied to claims 11, 13, 15 and 17 under 102 as discussed above and further in view of White et al (U.S. Patent 4,677,054).

Chang teaches the limitations of claims 11, 13, 15 and 17 as discussed above, including detection of HIV-1 using nucleic acid probes by dot blotting.

Chang does not teach the use of labels on the probes.

White teaches labeling probes and hybridization reagents using radioactive labels for detection of nucleic acids including RNA from animal tissue by hybridization (column 2, lines 6-34).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to combine the method of White with the method of Change because White states that the method is widely applicable, stating "It will be obvious to those skilled in the art that the method of the present invention is general in scope and can be used for DNA and mRNA-like analysis of all sorts of biological specimens (column 2, lines 40-44)." Further motivation to detect using these methods is provided by White, who notes "Very small amounts of sample can be tested.

Furthermore, the samples can be hybridized with multiple probes used in sequence (column 3, lines 2-4)". An ordinary practitioner would have been motivated to use the labels of White to detect HIV as taught by Chang since White says that the method is broadly applicable, permits the use of small sample amounts and permits detection using multiple different probes to enhance specificity.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is 703-308-6568. The examiner can normally be reached on 6:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

JEFFREY FREDMAN
PRIMARY EXAMINER
Jeffrey Fredman
Primary Examiner
Art Unit 1637

May 15, 2002